Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.16Same Quarter Last Year
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -5.44%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Neutral
The earnings call revealed strong revenue growth and customer satisfaction but was overshadowed by the revision of revenue guidance due to macroeconomic challenges and market competition. While European regulatory approval presents a long-term opportunity, short-term challenges persist, affecting performance and outlook.Company Guidance
During the recent RxSight conference call, the company provided revised guidance for fiscal year 2025, reflecting anticipated revenue in the range of $160 million to $175 million, down from the previous estimate of $185 million to $197 million. This adjustment reflects an implied revenue growth of 14% to 25% compared to 2024, a reduction from the initial 32% to 41% growth projection. The company anticipates selling more Light Delivery Devices (LDDs) in 2025 than in 2024, despite potential economic headwinds affecting Light Adjustable Lens (LAL) procedures. First-quarter 2025 revenue was reported at $37.9 million, marking a 28% increase from the same period in the previous year but a 6% sequential decline from the fourth quarter of 2024. The gross margin guidance remains unchanged at 71% to 73%, while operating expenses are adjusted to $150 million to $160 million, down from the prior forecast of $165 million to $170 million, reflecting a focus on aligning expenses with revenue growth.Revenue Growth
Preliminary first quarter 2025 revenue was $37.9 million, up 28% compared to the year-ago quarter.
European Regulatory Approval
RxSight reported European regulatory approval for their LDD and LAL, marking a significant step towards expanding into the EU market.
Customer Satisfaction
Customer satisfaction reached an all-time high of 97%, indicating strong approval of RxSight's products and services.
LDD Installed Base Growth
The LDD installed base grew to 1,044 units, up 43% compared to the end of the first quarter of 2024.
RXST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RXST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $14.90 | $13.23 | -11.21% |
Feb 25, 2025 | $29.21 | $28.97 | -0.82% |
Nov 07, 2024 | $50.85 | $48.01 | -5.59% |
Aug 05, 2024 | $40.78 | $47.85 | +17.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does RxSight (RXST) report earnings?
RxSight (RXST) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is RxSight (RXST) earnings time?
RxSight (RXST) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RXST EPS forecast?
RXST EPS forecast for the fiscal quarter 2025 (Q2) is -0.17.